Amarin shares soar after drug trial

THE most advanced in-trial drug of Dublin-headquartered bio-pharmaceutical company, Amarin is being tipped for “blockbuster” status, following successful Phase-3 trials.

The Nasdaq-listed company’s share price rose by 74%, yesterday, its highest in more than seven years.

Latest pre-marketing trials of the AMR101 cardiovascular treatment — aimed at proving its effectiveness in reducing triglyceride levels in patients with high triglycerides, without increasing “bad cholesterol” levels — proved successful, with its safety profile also impressing.